Intravenous fluosol in the treatment of acute myocardial infarction: Results of the thrombolysis and angioplasty in myocardial infarction 9 trial

Circulation

Volumn 90, Issue 1, 1994, Pages 114-120

  Wall, Thomas C ^a   Califf, Robert M ^a   Blankenship, James ^b   Talley, J David ^c   Tannenbaum, Mark ^d   Schwaiger, Markus ⁱ   Gacioch, Gerald ^e   Cohen, Mark D ^f   Sanz, Mark ^g   Leimberger, Jeffrey D ^a   Topol, Eric J ^h  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b GEISINGER MEDICAL CENTER   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

^d Mercy Hospital   (United States)

^e ROCHESTER GENERAL HOSPITAL   (United States)

^f St Francis Hospital   (United States)

^g St Patrick Hospital and Health Sciences Center   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Fluosol; myocardial infarction; radioisotopes; ventricles

Indexed keywords

ACETYLSALICYLIC ACID; FLUOSOL; HEPARIN; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE WALL MOTION; HEART MUSCLE ISCHEMIA; HEMATOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STROKE;

EID: 0028228939     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.90.1.114     Document Type: Article

References (21)

1. Jennings R, Reimer K. Factors involved in salvaging ischemic myocardium: effect of reperfusion of arterial blood. Circulation. 1983;68(suppl I):I-25. Abstract.
2. Califf R, Topol E, Gersh B. From myocardial salvage to patient salvage in acute myocardial infarction: the role of reperfusion therapy. J Am Coll Cardiol. 1989;14:1382-1388.
3. Braunwald E. Myocardial perfusion, limitation of infarct size, reduction of left ventricular dysfunction and improved survival: should the paradigm be expanded? Circulation. 1989;79:441-444.
4. Braunwald E, Kloner R. Myocardial reperfusion: a double-edged sword? J Clin Invest. 1985;76:1713-1719.
5. Forman MB, Virmani R, Puett DW. Mechanisms and therapy of myocardial reperfusion injury. Circulation. 1990;81(suppl IV): IV-69-IV-78.
6. Hirooka Y, Kudo H, Suzuki A. The effect of Fluosol-DA on the experimental myocardial infarction. Proceedings of the Fourth International Symposium on Perfluorochemical Blood Substitutes. Amsterdam, the Netherlands: Excerpta Medica; 1978:285-293.
7. Nunn G, Dance G, Peters J, Cohn L. Effect of fluorocarbon exchange transfusion on myocardial infarction size in dogs. Am J Cardiol. 1983;52:203-205.
8. Forman M, Bingham S, Kopelman H. Reduction of infarct size with intracoronary perfluorochemical in a canine preparation of reperfusion. Circulation. 1985;71:1060-1068.
9. Forman MB, Perry JM, Wilson BH, Verani MS, Kaplan PR, Shawl FA, Friesinger GC. Demonstration of myocardial reperfusion injury in humans: results of a pilot study utilizing acute coronary angioplasty with perfluorochemical in anterior myocardial infarction. J Am Coll Cardiol. 1991;18:911-918.
10. Virmani R, Forman MB, Kolodgie FD. Myocardial reperfusion injury: histopathological effects of perfluorochemical. Circulation. 1990;81(suppl IV):IV-57-IV-68.
11. Bajaj A, Cobb M, Virmani R, Gay JC, Light RT, Forman MB. Limitation of myocardial reperfusion injury by intravenous perfluorochemicals: role of neutrophil activation. Circulation. 1989;79: 645-656.
12. TIMI Study Group. The Thrombolysis in Myocardial Infarction trial. N Engl J Med. 1985;313:342-347.
13. Sandier H, Dodge HT. The use of single plane angiocardiograms for the calculation of left ventricular volume in man. Am Heart J. 1968;75:325-334.
14. Sheehan FH, Bolson EL, Dodge HT, Mathey DG, Schofer J, Woo HW. Advantages and applications of the centerline method for characterizing regional ventricular function. Circulation. 1986;74: 293-305.
15. Califf RM, Harrelson-Woodlief L, Topol EJ. Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. Circulation. 1990;82:1847-1853.
16. The GUSTO Investigators. An international randomized trial comparing four thrombolytic regimens consisting of tissue plasminogen activator, streptokinase, or both for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
17. Jennings RB, Reimer KA. Lethal reperfusion injury: fact or fancy? In Parratt JR, ed. Myocardial Response to Acute Injury. London, England: Macmillan Press Ltd; 1992:17-34.
18. Flaherty JT, Topol EJ, Pitt B, Gruber JW, Rothbaum DA, Heuser RR, George BS, Burwell LR, Kereiakes DJ, Deitchman D, Gustafson N, Brinker JA, Becker LC, Mancini GBJ, Werns SW. Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation. 1994;89:1982-1991.
19. Topol EJ, Ellis SG, Califf RM, George BS, Stump DC, Bates ER, Nabel EG, Walton JA, Candela RJ, Lee KL, Kline EM, Pitt B, the TAMI 4 Study Group. Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. J Am Coll Cardiol. 1989;14:877-884.
20. Harrison JK, Califf RM, Woodlief L, Kereiakes D, George BS, Stack RS, Ellis SG, Lee KL, O'Neill W, Topol EJ, the TAMI Study Group. Systolic left ventricular function therapy for acute myocardial infarction: an analysis of determinants of improvement. Circulation. 1993;87:1531-1541.
21. Forman MB, Ingram DA, Murray JJ. Role of perfluorochemical emulsions in the treatment of myocardial reperfusion injury. Am Heart J. 1992;124:1347-1357.